降钙素原预测危重癌症患者血流感染及支持治疗需求的效用
该回顾性研究分析了2200例疑似脓毒症的成人癌症患者的降钙素原(PCT)与血培养,发现血流感染(BSI)组PCT中位数更高(3.2 vs 0.5 ng/ml,p<0.001),PCT预测BSI的AUC为0.726(95%CI 0.698, 0.754)。PCT>2.0 ng/ml与BSI风险增加相关,且在粒细胞缺乏患者中关联更强(OR 9.09 vs 4.00,交互p=0.036),并与ICU入科时需血管加压药和肾脏替代治疗(RRT)相关。
要点
- PCT对危重癌症患者BSI有中等 discriminative 能力,AUC 0.726。
- PCT>2.0 ng/ml时粒细胞缺乏患者BSI风险更高(OR 9.09)。
- PCT>2.0 ng/ml与ICU血管加压药和RRT需求相关。
核心结论
- PCT是危重癌症患者(伴或不伴粒细胞缺乏)BSI的中等判别指标。
- PCT>2.0 ng/ml与ICU入科时需血管加压药和RRT显著相关。
研究设计与样本
- 回顾性分析2200例成人癌症疑似脓毒症患者的PCT和血培养。
- 主要结局为PCT采集后72小时内血培养阳性的BSI。
主要发现
- BSI组PCT中位数3.2 ng/ml,非BSI组0.5 ng/ml(p<0.001)。
- PCT预测BSI的AUC为0.726(95%CI 0.698, 0.754)。
- PCT>2.0 ng/ml与BSI关联:粒细胞缺乏OR 9.09(95%CI 4.39, 18.79),非粒细胞缺乏OR 4.00(95%CI 3.13, 5.10),交互p=0.036。
- PCT>2.0 ng/ml与血管加压药需求OR 1.82(95%CI 1.31, 2.53,p<0.001)和RRT OR 2.20(95%CI 1.24, 3.91,p=0.007)相关。
关键数值与推荐
- PCT>2.0 ng/ml为阈值,其与BSI的关联在粒细胞缺乏患者中更强。
- PCT>2.0 ng/ml与血管加压药和RRT需求的OR分别为1.82和2.20。
临床怎么用
- PCT>2.0 ng/ml可提示危重癌症患者BSI风险增加,尤其粒细胞缺乏者。
- PCT>2.0 ng/ml可辅助识别需血管加压药或RRT的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the diagnostic utility of procalcitonin (PCT) in predicting bacterial bloodstream infections (BSI) in critically ill cancer patients with and without neutropenia. We also investigated the role of PCT as a prognostic marker of supportive modalities (vasopressors, invasive mechanical ventilation, and renal replacement therapy (RRT)) in the intensive care unit (ICU). METHODS: We retrospectively analyzed 2200 PCT and blood cultures from adult cancer patients with suspected sepsis. Primary outcome was BSI, defined by positive blood culture, collected within 72 h of PCT collection. RESULTS: Median PCT values were higher in encounters with BSI (3.2 vs 0.5 ng/ml, p < 0.001). The area under the ROC curve (AUC) was 0.726 (95%CI 0.698, 0.754). PCT > 2.0 ng/ml was significantly associated with greater likelihood of BSI and this effect was significantly stronger for neutropenic (OR 9.09, 95%CI: 4.39, 18.79) compared with non-neutropenic patients (OR 4.00 (95% CI: 3.13, 5.10), interaction p = 0.036). PCT > 2.0 was associated with vasopressor requirement on ICU admission (OR 1.82 (95% CI 1.31, 2.53), p < 0.001) and RRT (OR 2.20 (95% CI 1.24, 3.91), p = 0.007). CONCLUSIONS: Procalcitonin is a fair discriminator of BSI in critically ill cancer patients with and without neutropenia and a PCT > 2.0 ng/ml was significantly more likely to require vasopressors and RRT in the ICU.
引用
- Blouin AG, Hsu M, Fleisher M, et al. Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients. Clin Chim Acta. 2020. PMID: 32679129. doi:10.1016/j.cca.2020.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。